Article

Pharmacokinetics-based identification of pseudoaldosterogenic compounds originating from Glycyrrhiza uralensis roots (Gancao) after dosing LianhuaQingwen capsule

Xiao-fang Lan1,2, Olajide E. Olaleye2, Jun-lan Lu1,2, Wei Yang3, Fei-fei Du2, Jun-ling Yang2, Chen Cheng2, Yan-hong Shi2, Feng-qing Wang2, Xue-shan Zeng2, Nan-nan Tian2, Pei-wei Liao2, Xuan Yu2, Fang Xu2, Ying-fei Li3, Hong-tao Wang4, Nai-xia Zhang2, Wei-wei Jia2, Chuan Li1,2
1 Graduate School, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China
2 State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
3 Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China
4 Hebei Yiling Chinese Medicine Research Institute, Shijiazhuang 050035, China
Correspondence to: Wei-wei Jia: weiweijia@simm.ac.cn, Chuan Li: chli@simm.ac.cn,
DOI: 10.1038/s41401-021-00651-2
Received: 18 January 2021
Accepted: 12 March 2021
Advance online: 30 April 2021

Abstract

LianhuaQingwen capsule, prepared from an herbal combination, is officially recommended as treatment for COVID-19 in China. Of the serial pharmacokinetic investigations we designed to facilitate identifying LianhuaQingwen compounds that are likely to be therapeutically important, the current investigation focused on the component Glycyrrhiza uralensis roots (Gancao). Besides its function in COVID-19 treatment, Gancao is able to induce pseudoaldosteronism by inhibiting renal 11β-HSD2. Systemic and colon-luminal exposure to Gancao compounds were characterized in volunteers receiving LianhuaQingwen and by in vitro metabolism studies. Access of Gancao compounds to 11β-HSD2 was characterized using human/rat, in vitro transport, and plasma protein binding studies, while 11β-HSD2 inhibition was assessed using human kidney microsomes. LianhuaQingwen contained a total of 41 Gancao constituents (0.01–8.56 μmol/day). Although glycyrrhizin (1), licorice saponin G2 (2), and liquiritin/liquiritin apioside (21/22) were the major Gancao constituents in LianhuaQingwen, their poor intestinal absorption and access to colonic microbiota resulted in significant levels of their respective deglycosylated metabolites glycyrrhetic acid (8), 24-hydroxyglycyrrhetic acid (M2D; a new Gancao metabolite), and liquiritigenin (27) in human plasma and feces after dosing. These circulating metabolites were glucuronized/sulfated in the liver and then excreted into bile. Hepatic oxidation of 8 also yielded M2D. Circulating 8 and M2D, having good membrane permeability, could access (via passive tubular reabsorption) and inhibit renal 11β-HSD2. Collectively, 1 and 2 were metabolically activated to the pseudoaldosterogenic compounds 8 and M2D. This investigation, together with such investigations of other components, has implications for precisely defining therapeutic benefit of LianhuaQingwen and conditions for its safe use.
Keywords: LianhuaQingwen; glycyrrhetic acid; 24-hydroxyglycyrrhetic acid; Gancao-induced pseudoaldosteronism; licorice- induced pseudoaldosteronism; 11β-hydroxysteroid dehydrogenase 2; COVID-19; colonic microbiota

Article Options

Download Citation

Cited times in Scopus